Personalized blood-thinning treatment for patients with blocked leg arteries
Panther (Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease)
This study is testing a new way to personalize blood-thinning treatments for people with blocked leg arteries to see if it can help those who don't respond well to standard medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Leicester Academic / other |
| Locations | 1 site (Leicester) |
| Trial ID | NCT06047002 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with peripheral arterial disease (PAD), a condition where blood vessels in the legs become blocked, increasing the risk of limb loss, heart attacks, and strokes. It aims to determine the prevalence of resistance to common antiplatelet medications, aspirin and clopidogrel, which are prescribed to reduce blood clotting and improve surgical outcomes. By identifying patients who do not respond to these medications, the study seeks to enhance treatment strategies and patient management. The research utilizes bedside testing technology to assess medication effectiveness in real-time.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with severely symptomatic peripheral arterial disease who are currently on antiplatelet therapy.
Not a fit: Patients under 18, those unable to provide consent, or individuals with acute limb ischaemia or severe diabetic foot sepsis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective personalized treatment plans for patients with PAD, reducing the risk of amputations and cardiovascular events.
How similar studies have performed: While the approach of assessing resistance to antiplatelet therapy is gaining traction, this specific study's methodology and focus on bedside testing represent a novel advancement in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over the age of 18 years. * Patients with severely symptomatic aorto-iliac and infra-inguinal peripheral arterial disease. * Patients with the ability to provide written informed consent. * Patients on antiplatelet therapy Exclusion Criteria: * Patients under the age of 18 years. * Patients unable or unwilling to provide written informed consent. * Patients with acute limb ischaemia of the lower limb. * Patients with aneurysmal disease of the arteries of the lower limb. * Patients with severe diabetic foot sepsis. * Patients with a known history of clotting disorders * Patients with inherited bleeding disorders
Where this trial is running
Leicester
- University Hospitals Leicester — Leicester, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Sarah Jane Messeder, MBChB — University of Leicester
- Study coordinator: Matt Bown, Professor
- Email: mjb42@le.ac.uk
- Phone: 0044 (0)116 2502381
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.